ARK Genomic Revolution ETF (ARKG) Analysis: Genomics Innovation's High-Stakes Momentum
Key Takeaways
- ARKG is an actively managed thematic ETF targeting companies driving the genomics revolution, with a focus on biotechnology and precision medicine across healthcare and related sectors.
- Portfolio features 40-60 holdings, concentrated in top names like CRSP (10.10%), TEM (8.58%), and TWST (8.21%), emphasizing gene editing and multiomic technologies.
- Expense ratio of 0.75% reflects active management; non-diversified structure amplifies exposure to biotech volatility and regulatory risks.
- Heavy healthcare sector weighting (over 85%) positions ARKG to capture structural shifts in precision therapies amid advancing CRISPR and AI-driven drug discovery.
- Key risks include FDA approvals, patent expirations, clinical trial outcomes, and heightened sensitivity to interest rates due to growth-oriented holdings.
- Recent market cycles highlight ARKG's potential for outsized gains tied to biotech catalysts like gene therapy breakthroughs.
ARK Genomic Revolution ETF (ARKG) Overview
The ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund seeking long-term capital growth by investing at least 80% of its assets in domestic and foreign equities relevant to the genomics revolution. Launched on October 31, 2014, and managed by ARK Investment Management LLC, ARKG targets companies across healthcare, information technology, materials, energy, and consumer discretionary sectors that stand to benefit from genomic advancements, such as precision therapies, multiomic technologies, programmable biology, and AI-integrated bioinformatics.
With a typical portfolio of 40-60 holdings, the fund maintains a concentrated, non-diversified structure. Top 10 holdings as of March 5, 2026, account for roughly 60% of assets: CRSP (CRISPR Therapeutics AG, 10.10%), TEM (Tempus AI Inc., 8.58%), TWST (Twist Bioscience Corp., 8.21%), TXG (10x Genomics Inc., 5.98%), PSNL (Personalis Inc., 5.94%), BEAM (Beam Therapeutics Inc., 5.02%), ILMN (Illumina Inc., 4.17%), NTRA (Natera Inc., 4.07%), GH (Guardant Health Inc., 3.97%), and RXRX (Recursion Pharmaceuticals, 3.76%). Sector exposure is dominated by healthcare (approximately 87%), with information technology comprising about 11% and minor allocations elsewhere. The expense ratio stands at 0.75%, and the fund rebalances dynamically based on ARK's proprietary research without a fixed index.
Industry and Thematic Landscape
The genomics revolution encompasses breakthroughs in DNA sequencing, gene editing like CRISPR-Cas9 and base editing, multiomics data integration, and AI-powered precision medicine. This thematic space is propelled by structural growth drivers, including the rising prevalence of genetic disorders, demand for personalized therapies, and expanding applications in agriculture and industrial biotech. The global genome editing market is projected to grow from around $5 billion in 2026 to over $13 billion by 2035, fueled by clinical advancements in curative treatments for rare diseases.
Regulatory developments add momentum: the FDA's "Plausible Mechanism" pathway accelerates approvals for N-of-1 therapies, while EU reforms like the Pharmaceutical Package aim to streamline biotech R&D. Capital flows into biotech have rebounded, supporting M&A and venture funding, though geopolitical tensions and supply chain scrutiny via acts like the U.S. Biosecure Act pose hurdles. Key risks include stringent FDA oversight, ethical debates on germline editing, intellectual property disputes, and reimbursement pressures on innovative drugs.
Performance and Positioning Snapshot
In recent market cycles, ARKG has exhibited characteristic volatility tied to biotech sector dynamics. Following sharp declines in 2022 and 2024 amid elevated interest rates and trial setbacks, the fund posted strong gains in 2025, with year-end NAV returns around 23%, outpacing broader health benchmarks. This rebound aligned with favorable macro shifts, including anticipated rate cuts easing pressure on growth stocks, positive clinical readouts in gene editing, and renewed investor appetite for innovation post-earnings seasons. Recent trading sessions reflect ongoing sensitivity to headlines on CRISPR trials and AI-biotech synergies, underscoring ARKG's beta exceeding 2.5 relative to the S&P 500. Positioning remains growth-oriented, with active adjustments amplifying exposure to high-conviction genomics leaders amid sector rotation toward healthcare disruptors.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform’s top-performing AI trading bots under prevailing market conditions. Tickeron provides hundreds of AI bots scanning thousands of tickers across diverse strategies, timeframes, and performance metrics, from momentum and mean reversion to options trading. Only the strongest, real-time performers rise to this curated section, helping investors identify tools aligned with current volatility, trends, and opportunities like biotech rallies. Explore these bots to enhance your trading edge with data-driven automation—review strategies and backtests today.
2026 Outlook and Key Factors to Monitor
Heading into 2026, ARKG's fortunes hinge on the maturation of genomics platforms amid converging innovation platforms like AI and robotics. Structural drivers include accelerating clinical adoption of CRISPR-based therapies, with in vivo editing trials expanding and FDA pathways like Plausible Mechanism fast-tracking rare disease treatments. Multiomics integration promises to refine precision medicine, boosting demand for holdings in sequencing (TXG, ILMN) and AI-drug discovery (TEM, RXRX). Genome editing markets are forecasted to surge at double-digit CAGRs, supported by rising R&D funding and M&A in biotech.
Macro risks loom, including persistent inflation delaying rate relief, which could pressure unprofitable growth names comprising much of ARKG's small- and mid-cap exposure. Policy shifts, such as U.S. drug pricing reforms or EU sustainability mandates, may impact reimbursements. Competitive pressures from passive biotech ETFs and rivals like IBB intensify scrutiny on ARK's active picks. Earnings cycles for top holdings will be pivotal, alongside regulatory milestones like FDA nods for gene therapies. Balanced capital flows into healthcare thematics could sustain inflows, but non-diversification amplifies single-stock and sector risks. Investors should monitor biotech M&A velocity and trial success rates for sustained upside potential.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for ARKG turns positive, indicating new upward trend
ARKG saw its Momentum Indicator move above the 0 level on May 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARKG just turned positive on May 26, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
ARKG moved above its 50-day moving average on May 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for ARKG moved above the 200-day moving average on May 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ARKG moved out of overbought territory on June 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 78 cases where ARKG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ARKG broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARKG entered a downward trend on May 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health